- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04506801
The Effect of Probiotics on Functional Constipation in the Elderly
August 6, 2020 updated by: Katarina Fehir Šola
The main scope of the proposed research in the framework is to investigate the effect of probiotic bacteria Lactobacillus acidophilus LA3, Bifidobacterium animalis ssp.
lactis BLC1 i Lactobacillus casei BGP93 on functional constipation and on the quality of life of the elderly in a nursing home.
The experimental part will consists of double-blind, placebo-controlled clinical trial over 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
During the first four weeks, the subjects were monitored primarily concerning bowel discharges and general health.
After that initial four weeks, they are re-evaluated compliance with inclusion and exclusion criteria.
Participants were allocated to the double-blind section of the trial (12 weeks), using o computer-generated to a placebo group or in the probiotic group in the form of a liquid oral formulation once a day.
On first day of intervention participants provide a blood sample.
All investigators, participants and study personnel were blinded to the order of randomization.
Participants were told to consume 9 drops of study probiotics once a day for next 12-week intervention.
On last day of intervention, participants provide a blood sample.
The last four weeks of the double-blind section (week 9-12) participants an evaluation period in which the respondents were evaluated for the outcomes of the study.
After completing the double-blind study, the participants were followed for an additional four weeks.
Inclusive / Excluded criteria are evaluated on two occasions, at the time of inclusion in the 4-week introductory section and its end.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bjelovar, Croatia, 43000
- Katarina Fehir Šola
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 65 years or more
- signed informed consent for study participation
- functional constipation defined by Rome IV criteria
- ability to understand the procedure
Exclusion Criteria:
- suspicion of obstructive ileus or previous obstructive ileus
- suspected or confirmed diagnosis: irritable colon syndrome, ulcerative colitis, Crohn's disease, malignant digestive tract disease
- diarrhoea of any cause within the last month
- acute infectious disease within the last month excluding people who use antibiotics
- persons who have opioid analgesics in pharmacotherapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
liquid oral formulation 9 drops once a day
|
Participants were told to consume 9 drops of study placebo one a day for the next 12-week intervention
|
|
Experimental: Probiotic
The probiotic contained Lactobacillus acidophilus LA3; 1 · 1011 CFU / g, Bifidobacterium animalis subsp.
Lactis BLC1; 1.5 · 1011 CFU / g and Lactobacillus casei BGP93 2 · 1011cfu / g in the form of a liquid oral formulation
|
Participants were told to consume 9 drops of study probiotics/placebo once a day for next 12-week intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in stool frequency in patients who use probiotics
Time Frame: 12 weeks
|
The proportion of subjects who meet the criterion of "normal bowel movement" according to the Roman IV criteria, at least 3 times a week to no more than 3 times a day.
This proportion will be determined for each of the 4 evaluation weeks and will be analyzed as a time-averaged proportion.
The proportion will be estimated on the basis of the subjects' diaries in which, by days, with indicated dates, the subjects will record each bowel emptying.
Investigators would inform the evidence base with regards to the multi-strained probiotic efficacy in treating constipation among the elderly.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in hs-CRP at the blood of a patient who uses probiotics determined by immunoturbidimetric method
Time Frame: 12 weeks
|
The secondary outcome is to investigate the effect of selected probiotic strains on the concentration of the marker of inflammation, hs c-reactive protein (hs-CRP) in the serum of the subjects.
hs-CRP will be determined by the immunoturbidimetric method.
Investigators wanted to study the effect of this multi-strained probiotic on clinical and laboratory parameters.
Blood was collected before the probiotic intervention and after 12 weeks.
|
12 weeks
|
|
Change in glucose parameters of a patient who use probiotics determined by standard laboratory methods
Time Frame: 12 weeks
|
Values of laboratory indicators - glucose metabolism will be monitored.
Investigators wanted to study the effect of this multi-strained probiotic on glucose parameters.
Blood was collected like in Outcome2, before the intervention and after the intervention.
|
12 weeks
|
|
Change in blood parameters- triglycerides of a patient who use probiotics determined by standard laboratory methods.
Time Frame: 12 weeks
|
Values of laboratory indicators of lipid metabolism - triglycerides will be monitored.
Blood was collected before and after the intervention.
Investigators wanted to study the effect of multi-strain probiotics on triglycerides.
|
12 weeks
|
|
Change in blood parameter- total cholesterol of a patient determined by standard laboratory methods
Time Frame: 12 weeks
|
Investigator monitoring change of laboratory indicators of total cholesterol in beginning and at the end of the intervention with multi-strain probiotics.
|
12 weeks
|
|
Change in HDL cholesterol in blood parameters of a patient who use probiotics determined by standard laboratory methods
Time Frame: 12 weeks
|
Values of laboratory indicators of HDL (high density lipoprotein) will be monitoring during the intervention.
Blood samples were collected before and after the intervention.
|
12 weeks
|
|
Change in LDL cholesterol at the blood of patients who use probiotics determined by standard laboratory methods
Time Frame: 12 weeks
|
Investigator monitoring change of laboratory indicators of LDL(low density lipoprotein), before study and at the end of the intervention.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 25, 2018
Primary Completion (Actual)
March 25, 2019
Study Completion (Actual)
May 25, 2019
Study Registration Dates
First Submitted
July 29, 2020
First Submitted That Met QC Criteria
August 6, 2020
First Posted (Actual)
August 10, 2020
Study Record Updates
Last Update Posted (Actual)
August 10, 2020
Last Update Submitted That Met QC Criteria
August 6, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 380-130/134-19-4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
all IPD that underlie results in a publication
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Constipation
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
Wecare Probiotics Co., Ltd.Not yet recruiting
-
Federal University of Minas GeraisMax NutriRecruiting
-
Peking Union Medical College HospitalInstitute of Process Engineering, Chinese Academy of SciencesNot yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota TransplantationChina
-
Liaquat University of Medical & Health SciencesUniversità degli Studi dell'InsubriaNot yet recruiting
-
Universidad de AntioquiaNot yet recruitingConstipation - Functional
-
Eskisehir Osmangazi UniversitySehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research HospitalCompletedConstipation - FunctionalTurkey (Türkiye)
-
Ahi Evran University Education and Research HospitalActive, not recruitingConstipation - FunctionalTurkey (Türkiye)
-
Peking Union Medical College HospitalRecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)China
-
Zeynep Idil SevimliNot yet recruitingFunctional Constipation (FC)Turkey (Türkiye)
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of